TMZ-BioShuttle - A reformulated temozolomide

International Journal of Medical Sciences

Volumn 5, Issue 5, 2008, Pages 273-284

  Waldeck, Waldemar ^a   Wiessler, Manfred ^a   Ehemann, Volker ^b   Pipkorn, Ruediger ^a   Spring, Herbert ^a   Debus, Juergen ^b   Didinger, Bernd ^b   Mueller, Gabriele ^a   Langowski, Joerg ^a   Braun, Klaus ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

BioShuttle; Carrier molecules; Drug delivery; Facilitated transport; Glioblastoma multiforme (GBM); Reformulation; Temozolomide (TMZ)

Indexed keywords

TEMOZOLOMIDE;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULARY; DRUG SYNTHESIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; PROSTATE CANCER;

EID: 54749123594     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.5.273     Document Type: Article

References (48)

1. Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia. 2007; 13: 233-43.
2. Johnson JL, Yalkowsky SH. Reformulation of a new vancomycin analog: an example of the importance of buffer species and strength. AAPS PharmSciTech. 2006; 7: E5.
3. O'Riordan TG. Optimizing delivery of inhaled corticosteroids: matching drugs with devices. J Aerosol Med. 2002; 15: 245-50.
4. Roy V, Perez EA. New therapies in the treatment of breast cancer. Semin Oncol. 2006; 33: S3-S8.
5. Marchesi F, Turriziani M, Tortorelli G, et al. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res. 2007; 56: 275-87.
6. Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther. 2001; 1: 13-9.
7. Shinoura N, Yamada R, Tabei Y, et al. [Temozolomide-temodal.]. Gan To Kagaku Ryoho. 2008; 35: 543-7.
8. Mutter N, Stupp R. Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther. 2006; 6: 1187-204.
9. Denny BJ, Wheelhouse RT, Stevens MF, et al. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry. 1994; 33: 9045-51.
10. Cai Y, Wu MH, Xu-Welliver M, et al. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cancer Res. 2000; 60: 5464-9.
11. Hirose Y, Kreklau EL, Erickson LC, et al. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg. 2003; 98: 591-8.
12. Riccardi A, Mazzarella G, Cefalo G, et al. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. Cancer Chemother Pharmacol. 2003; 52: 459-64.
13. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. Drug Discov Today. 2003; 8: 1128-37.
14. Kolb HC, Finn MG, Sharpless KB. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl. 2001; 40: 2004-21.
15. Kohn M, Breinbauer R. The Staudinger ligation - a gift to chemical biology. Angew Chem Int Ed Engl. 2004; 43: 3106-16.
16. Chandra RA, Douglas ES, Mathies RA, et al. Programmable cell adhesion encoded by DNA hybridization. Angew Chem Int Ed Engl. 2006; 45: 896-901.
17. Rostovtsev VV, Green LG, Fokin VV, et al. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew Chem Int Ed Engl. 2002; 41: 2596-9.
18. Bachmann WE, Deno NC. The Diels-Alder Reaction of 1-Vinylnaphthalene with a,@- and a,p,y,G- Unsaturated Acids and Derivatives. J Americ Chem Soc. 1949; 71: 362-3.
19. Reppe W, Schlichting O, Klager K, et al. Cyclisierende Polymerisation von Acetylen I. Justus Liebigs Annalen der Chemie. 1948; 560: 1-92.
20. Merriefield RB. Solid Phase Peptide Synthesis. I The Synthesis of a Tetrapeptide. J Americ Chem Soc. 1963; 85: 2149-54.
21. Ahn JY, Hu Y, Kroll TG, et al. PIKE-A is amplified in human cancers and prevents apoptosis by up-regulating Akt. Proc Natl Acad Sci U S A. 2004; 101: 6993-8.
22. Stone KR, Mickey DD, Wunderli H, et al. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978; 21: 274-81.
23. Ehemann V, Sykora J, Vera-Delgado J, et al. Flow cytometric detection of spontaneous apoptosis in human breast cancer using the TUNEL-technique. Cancer Lett. 2003; 194: 125-31.
24. Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991; 139: 271-9.
25. Singer S, Ehemann V, Brauckhoff A, et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology. 2007;46(3):759-68.
26. Tschaharganeh D, Ehemann V, Nussbaum T, et al. Non-specific Effects of siRNAs on Tumor Cells with Implications on Therapeutic Applicability Using RNA Interference. Pathol Oncol Res. 2007; 13: 84-90.
27. Braun K, Peschke P, Pipkorn R, et al. A biological transporter for the delivery of peptide nucleic acids (PNAs) to the nuclear compartment of living cells. J Mol Biol. 2002; 318: 237-43.
28. Braun K, von BL, Pipkorn R, et al. BioShuttle-mediated plasmid transfer. Int J Med Sci. 2007; 4: 267-77.
29. Heckl S, Debus J, Jenne J, et al. CNN-Gd(3+) Enables Cell Nucleus Molecular Imaging of Prostate Cancer Cells: The Last 600 nm. Cancer Res. 2002; 62: 7018-24.
30. Heckl S, Pipkorn R, Waldeck W, et al. Intracellular Visualization of Prostate Cancer Using Magnetic Resonance Imaging. Cancer Res. 2003; 63: 4766-72.
31. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992; 65: 287-91.
32. van Brussel JP, Busstra MB, Lang MS, et al. A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol. 2000; 45: 509-12.
33. Monti B, Zanghellini P, Contestabile A. Characterization of ceramide-induced apoptotic death in cerebellar granule cells in culture. Neurochem Int. 2001; 39: 11-8.
34. Lukusa T, Fryns JP. Human chromosome fragility. Biochim Biophys Acta. 2008; 1779: 3-16.
35. Kristeleit R, Stimson L, Workman P, et al. Histone modification enzymes: novel targets for cancer drugs. Expert Opin Emerg Drugs. 2004; 9: 135-54.
36. Bignold LP. Alkylating agents and DNA polymerases. Anticancer Res. 2006; 26: 1327-36.
37. Park JA, Joe YA, Kim TG, et al. Potentiation of antiglioma effect with combined temozolomide and interferon-beta. Oncol Rep. 2006; 16: 1253-60.
38. Thomas HC, Lame MW, Wilson DW, et al. Cell cycle alterations associated with covalent binding of monocrotaline pyrrole to pulmonary artery endothelial cell DNA. Toxicol Appl Pharmacol. 1996; 141: 319-29.
39. Barman HK, Takami Y, Ono T, et al. Histone acetyltransferase 1 is dispensable for replication-coupled chromatin assembly but contributes to recover DNA damages created following replication blockage in vertebrate cells. Biochem Biophys Res Commun. 2006; 345: 1547-57.
40. Hirose Y, Katayama M, Stokoe D, et al. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol. 2003; 23: 8306-15.
41. Rao PN. The molecular basis of drug-induced G2 arrest in mammalian cells. Mol Cell Biochem. 1980; 29: 47-57.
42. Xie CH, Naito A, Mizumachi T, et al. Mitochondrial regulation of cancer associated nuclear DNA methylation. Biochem Biophys Res Commun. 2007; 364: 656-61.
43. Patra SK, Patra A, Zhao H, et al. DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog. 2002; 33: 163-71.
44. Nakayama M, Gonzalgo ML, Yegnasubramanian S, et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem. 2004; 91: 540-52.
45. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008; 26: 4189-99.
46. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-96.
47. Torchilin VP. Drug targeting. Eur J Pharm Sci. 2000; 11 (Suppl 2): S81-S91.
48. Braun K, Pipkorn R, Waldeck W. Development and Characterization of Drug Delivery systems for Targeting Mammalian Cells and Tissues: A Review. Curr Med Chem. 2005; 12: 1841-58.